Big Easy Weightloss Review

What Big Easy Weightloss charges

• Semaglutide: $399 — for twelve weeks, struck through from $495; the product page itself still prints "Starting at $495 /12 week plan"
• Tirzepatide: $499 — for twelve weeks, struck through from $599; the product page itself still prints "Starting at $599 / 12 week plan"
• Sermorelin: $267 — starting at, for an eight-week plan; a combined sermorelin-and-NAD+ card carries the same figure for both
• NAD+: $267 — starting at, for an eight-week plan; a combined sermorelin-and-NAD+ card carries the same figure for both

It names the pharmacies and publishes their gaps

Its pharmacy page names Apothecary Pharma and BPI Labs as outsourcing facilities, and OptioRx, Hallandale Pharmacy, Miller's Pharmacy and Boudreaux's New Drug Store as traditional compounders, with OptioRx described as a network including SBH, Enovex and Braun.

Beside several of them it prints the states each cannot ship to — Hallandale lists nine, Boudreaux's lists four and Miller's lists one — and its FAQ adds Nova, PQ, Olympia, Medivant, Seven Cells and Red Rock.

Publishing a dispenser's shipping exclusions is rare, and it is what makes the rest of this review checkable at all.

Three of those pharmacies have their own federal letters

Apothecary Pharma, LLC received a warning letter in December 2025 for compounding pharmacy and adulterated drug products, and Tailstorm Health Inc. trading as Medivant Health received one in April 2025 under the same subject.

BPI Labs, LLC received one in March 2025 for unapproved new drugs and misbranding.

Those three letters were issued to those three pharmacies. None was issued to Big Easy Weightloss, which carries no federal letter of its own; they matter here only because the seller names those companies as possible dispensers.

The fifty-state claim loses on its own site, three times over

It says "We currently serve ALL 50 states". Its FAQ then carries a heading beginning "You don't serve XXX state", and a separate sentence says it has "our physicians applying for those remaining states we don't cover".

Six published pharmacy-level exclusion lists say the same thing a fourth way.

No coverage claim is credited here. The seller's own pages outvote its own headline.

The price depends on which pharmacy you pick

Each product card carries a Choose Your Pharmacy control, so the figure a reader sees is the page default rather than the price they will pay.

The pricing page and the product pages then disagree: the pricing page shows a discounted package figure while the product page still advertises the higher one it was struck through from.

Its candour elsewhere is genuine. In its own words compounded medications "are NOT FDA-approved finished drug products" and "may pose higher risks compared to FDA-approved products, including potential variability in strength, quality, and purity" — a warning most sellers do not write about their own goods.

How we verified this

• Read the pharmacy page and the FAQ together and counted eleven named dispensers, recording the six published exclusion lists as the seller prints them.
• Declined a combined sermorelin-and-NAD+ card because one figure covered two compounds, and took each figure from the compound's own product page instead.
• Read the fifty-state sentence against the FAQ heading, the still-applying sentence and the exclusion lists, and credited no coverage claim.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand as Big Easy and Big Easy Weightloss against the live federal warning-letter table, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run; no letter attaches to this seller, and the three letters found belong to Apothecary Pharma, BPI Labs and Medivant Health as separate companies.